Human papillomavirus infection (hpv) & screening strategies for cervical cancer

Indian Journal of Medical Research

Volumn 130, Issue 3, 2009, Pages 234-240

  Sehgal, Ashok ^a   Singh, Veena ^a  

^a Institute of Cytology and Preventive Oncology ICMR   (India)

Author keywords

Cervical cancer; Cytology based screening; HPV; HPV DNA; Visual screening

Indexed keywords

ACETIC ACID; LUGOL; VIRUS DNA;

CANCER CONTROL; CANCER SCREENING; DEVELOPING COUNTRY; FEASIBILITY STUDY; HEALTH CARE ACCESS; HUMAN; MALIGNANT TRANSFORMATION; MICROSCOPY; NONHUMAN; PAPANICOLAOU TEST; POLYMERASE CHAIN REACTION; PRIMARY PREVENTION; QUALITY CONTROL; REVIEW; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VIRUS CARCINOGENESIS; VIRUS DETECTION; VIRUS INFECTION; WART VIRUS;

DNA, VIRAL; FEMALE; HUMANS; INDIA; MASS SCREENING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 72649104621     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Sherris JD, Wells ES, Tsu VD, Bishop A. Cervical cancer in developing countries: A situation analysis. A World Bank Womens health and nutrition working paper. Washington DC: World Bank; 1993.
2. WHO meeting. Control of cervical cancer. Bull World Health Organ 1986, 64: 607-18.
3. Natural history of cervical cancer. In: Planning appropriate cervical cancer prevention programs, 2nd ed. Seattle WA 98109, USA, PATH; 2000. p. 7-10.
4. Richart RM, Barron BA. A follow-up of patients with cervical dysplasia. Am J Obstet Gynaecol 1969; 105: 386-93.
5. Hildescheim A, Schiffman MH, Gravit PE, Glass AG, Greer CE, Zihang T, et al. Persistence of type specific human papilloma virus infection among cytologically normal women. J Infect Dis 1994; 169: 235-40.
6. Carter JJ, Koutsky LA, Wipf GC, Christercen ND, Lee SK, Kuypers J, et al. The natural history of human papillomavirus type 16 capsid antigen among cohort of university women. J Infect Dis 1996; 174: 927-36.
7. Schneider A. Latent and subclinical genital HPV infections. Papillomavirus Rep 1990; 1: 2-5.
8. Richart M, Masood S, Syrjanen KJ, Vassilakos P, Kaufman RH, Meisels A, et al. Human papillomavirus - An IAC task force summary. Acta Cytol 1998; 42: 50-8.
9. Cullen AP, Reid R, Campion M, Lrincz AT. An analysis of the physical state of different human papillomavirus DNAs in intraepithelial and invasive cervical neoplasia. J Virol 1991; 65: 606-9.
10. IARC working group on cervical cancer screening. Summary chapter. In: Hakama M, Miller AB, Day NE, editors. Screening for cancer of the uterine cervix, IARC Scientific Publication, 7. Lyon: IARC; Scientific Publication; 1986. p. 133-44.
11. Hakama M, Rasanen-Virtanen U. Effective of mass screening program on the risk of cervical cancer. Am J Epidemiol 1989; 17: 173-204.
12. Laara E, Day NE, Hakama M. Trends in mortality from cervical cancer in the Nordic countries: Association with organized screening programs. Lancet 1987; I: 1247-9.
13. Anderson GH, Boyes DA, Benedet JL, Le Riche JC, Matisic JP, Suen KC, et al. Organization and results of cervical cytology screening program in British Columbia 1955-85. Br Med J 1988; 296: 975-8.
14. Nanda K, McCrory DC, Myers ER, Bastian LA, Hasselblad V, Hickey JD, et al. Accuracy of the papanicoalou test in screening for an follow up of cervical cytologic abnormalities; a systemic review. Ann Intern Med 2000; 132: 810-9.
15. Fahey M, Irwig L, MeCaskill. Metaanalysis of pap test accuracy. Am J Epidemiol 1995; 141: 680-9.
16. Lozcano-Ponce EC, Moss S, Alonso de Ruiz P, Salmeron Castro J, Hernandez Avila M. Cervical cancer screening in developing countries: why is it ineffective? The case of Mexico. Arch Med Res 1999; 30: 240-50.
17. Sankarnarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009; 360: 1385-94.
18. Brown AO, Gerber AM. Cost effectiveness of 3 methods to enhance the sensitivity of papanicolaou testing. JAMA 1999; 281: 347-53.
19. Limaya A, Connor AJ, Huan x, Luff R. Comparative analysis of conventional papanicolaou tests and a fluid based thin layer method. Arch Pathol Lab Med 2003; 127: 2003-4.
20. Monsonego J, Bosch Fx, Coursaget P, Cox JT, Franco E, Frazer I, et al. Cervical cancer control, priorities and new directions: A mini review. Int J Cancer 2004; 108: 329-33.
21. University of Zimbabwe/ JHPIEGO cervical cancer project. Visual inspection with acetic acid for cervical cancer screening: test qualities in a primary care setting. Lancet 1999; 353: 869-73.
22. Betinson J, Qiao YL, Pretorius R, Zhang WH, Elson P, Li L, et al. Shanxi province cervical cancer screening study. A cross sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol Oncol 2001; 83: 439-44.
23. Sankaranarayanan R, Wesley R, Thara S, Dhakad N, Chandralekha B, Sebastian P, et al. Test characteristics of visual inspection with 4% acetic acid (VIA) and Lugo's iodine (VILI) in cervical cancer screening in Kerala, India. Int J Cancer 2003; 106: 404-8.
24. Sankarayanaryanan R, Basu P, Wesley R, Mahe C, Keita N, Mbalawa CC, et al. For the IARC multicentric study group on cervical cancer early detection. Accuracy of visual screening for cervical neoplasia: Results from an IARC multicentric study in India and Africa. Int J Cancer 2004; 110: 907-13.
25. Wright TC Jr. Cervical cancer screening using visualization techniques. J Natl Cancer Inst Monogr 2003; 31: 66-71.
26. Sankaranarayanan R, Esmy PO, Rajkumar R, Muwonge R, Swaminathan R, Shanthakumari S, et al. Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomized trial. Lancet 2007; 370: 398-406.
27. Basu PS, Sankaranarayanan R, Mandal R, Roy C, Das P, Choudhury D, et al. Visual inspection with acetic acid and cytology in the early detection of cervical neoplasia. Int J Gynecol Cancer 2003; 13: 626-32.
28. Goldie SJ, Kuhn L, Denny L, Pollack A, Wright TC. Policy analysis of cervical cancer screening strategies in low resource settings: clinical benefits and cost effectiveness. JAMA 2001; 285: 3107-15.
29. Screening: Visual approaches. In: Planning appropriate cervical cancer prevention programmes. Seattle WA USA: PATH; 2000. p. 15-8.
30. Cuzick J. Human papilloma virus testing for primary cervical cancer screening (editorial). JAMA 2000; 283: 108-9.
31. Qu W, Jiang G, Cruz Y, Chang CJ, Ho GY, Klein RS, et al. PCR detection of human papillomavirus: comparison between MY09/MY11 and GP5+/GP6+ primer systems. J Clin Microbiol 1997; 35: 1304-10.
32. de Roda Husman AM, Walboomers JMM, Van den Brule AJ, Meijer CJ, Snijders PJ. The use of general primary GP5 and GP6 elongated at their 3' ends with adjacent highly conserved sequences improves human papillomavirus detection by polymerase chain reaction. J Gen Virol 1995; 76: 1057-62.
33. Kulasingham SL, Hughes JP, Kiviat NB, Mao C, Weiss NS, Kuypers JM, et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities. Comparison of sensitivity, specificity and frequency of referral. JAMA 2002; 288: 1749-57.
34. ALT study group. Human papillomavirus testing for triage of women with cytologic evidence of low grade squamous intraepithelial lesions. Baseline data from a randomized trial. J Natl Cancer Inst 2000; 92: 397-402.
35. Kuhn L, Denny L, Pollock A, Lorincz A, Richart RM, Wright TC. Human papillomavirus DNA testing for cervical cancer screening in low resource settings. J Natl Cancer Inst 2000; 92: 818-25.
36. Preventing cervical cancer in low-resource setting. In: Cervical cancer update, outlook, vol.18, Seatle Washington: PATH; 2000. p. 1-8.
37. Qiao YL, Sellors JW, Eder PS, Bao YP, Lim JM, Zhao FH, et al. A new HPV-DNA test for cervical cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol 2008; 9: 929-36.
38. Sellors J, Lorincz A, Mahony J, Mielzynska I, Lytwyn A, Roth P, et al. Comparison of self collected vaginal, vulvar and urine samples with physician collected cervical samples for human papillomavirus testing to detect high grade squamous intraepithelial lesions. Can Med Assoc J 2000; 163: 513-8.